WILMINGTON, Del., Oct. 13, 2023 /PRNewswire/ -- SPI Pharma, Inc. (SPI) and Q-Vant Biosciences, Inc. (Q-Vant) have partnered to leverage Q-Vant's leadership in unique, sustainable saponin extraction technology with SPI's global pharmaceutical reach and expertise in servicing the industry. The investment commitment to expand commercial-scale GMP manufacturing of high-purity saponins, along with the exclusive commercial agreement, will enable global pharma customers to access a sustainable, scalable, and fully integrated supply of saponin adjuvants.
SPI Pharma In Grand Haven, USA Receives Excipact Gmp Certification As Pharmaceutical Excipient Supplier
SPI Pharma, Inc. Announces signing of Regional Sole Distribution Agreement for ACTILLETS™ MCC Microcrystalline Cellulose Pellets, TAP® Tartaric Acid Pellets and Directly Compressible Ibuprofen DC100 with ingredientpharm
CPHI Frankfurt 2022 SPI Pharma is attending CPHI Frankfurt on November 1st – 3rd 2022
Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced on Oct. 4, 2019 that it will further enhance and develop an existing collaboration in Japan with Summit Pharmaceuticals International Corporation (SPI), a wholly owned subsidiary of Sumitomo Corporation. Through its collaboration with SPI, Rentschler Biopharma has secured new contracts with Japanese pharmaceutical companies. SPI and Rentschler Biopharma are working together with Japanese clients to outline projects from early clinical stage up to commercial launch and to ensure optimal service.
The pjarmaceutical excipient, intended for use in the formulation of flash orally dissolving tablets, is designed to disintegrate in less than 10 seconds.
 SPI Pharma, a leading supplier of solutions to pharmaceutical formulation marketers is pleased to announce a new, exclusive agreement with Azelis Americas, a leading innovation service provider in the specialty chemicals and food ingredients industry. In the agreement, Marcor, an Azelis Americas company will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace.Â
SPI Pharma introduces UltraBurst™, providing a step-change in the most critical orally disintegrating tablet (ODT) characteristics — dissolution time. It is an innovative excipient platform for flash ODTs, enabling disintegration in under ten seconds.
SPI Pharma Featured in PMPS February Edition!
SPI Pharma Names New CEO